利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

52 条记录 (耗时 0.026 秒)

    Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds
    1.
    发明申请
    Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds 审中-公开
    包含芳基杂环化合物的纳米微粒和控制释放组合物

    公开(公告)号：US20110008435A1

    公开(公告)日：2011-01-13

    申请号：US11672263

    申请日：2007-02-07

    申请人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    发明人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/14 ,  A61K31/496 ,  A61P25/18

    CPC分类号： A61K9/5084

    摘要： The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.

    摘要翻译： 本发明提供一种包含齐拉西酮的组合物，其可用于治疗和预防精神分裂症和类似的精神障碍。 在一个实施方案中，组合物包含包含齐拉西酮和至少一种表面稳定剂的纳米颗粒颗粒。 纳米颗粒具有小于约2000nm的有效平均粒度。 在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送齐拉西酮。 本发明还涉及含有这些组合物的剂型，以及治疗和预防精神分裂症和类似精神障碍的方法。

    Topiramate pharmaceutical composition
    3.
    发明申请
    Topiramate pharmaceutical composition 审中-公开
    托吡酯药物组成

    公开(公告)号：US20060121112A1

    公开(公告)日：2006-06-08

    申请号：US11297737

    申请日：2005-12-08

    申请人： Scott Jenkins ,  Gary Liversidge

    发明人： Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K31/7008 ,  A61K9/22

    CPC分类号： A61K9/5084 ,  A61K31/7008

    摘要： A once daily controlled-release pharmaceutical formulation which contains therapeutic amounts of topiramate and which is capable of being administered to specific regions along the gastrointestinal tract used to treat various types of conditions, for example, partial seizures with or without secondarily generalized seizures, primary generalized tonic-clonic seizures, seizures associated with Lennox Gastaut Syndrome, migraines, and obesity.

    摘要翻译： 一种每日一次的控释药物制剂，其含有治疗量的托吡酯，其能够被施用于沿着胃肠道的特定区域，用于治疗各种类型的病症，例如具有或不具有二次全身性发作的部分性发作， 强直阵挛性发作，与Lennox Gastaut综合征相关的癫痫发作，偏头痛和肥胖。

    Multiparticulate modified release composition
    4.
    发明授权
    Multiparticulate modified release composition 有权
    多微粒改性组合物

    公开(公告)号：US06902742B2

    公开(公告)日：2005-06-07

    申请号：US10331754

    申请日：2002-12-30

    申请人： John G. Devane ,  Paul Stark ,  Niall M. M. Fanning ,  Gurvinder Singh Rekhi

    发明人： John G. Devane ,  Paul Stark ,  Niall M. M. Fanning ,  Gurvinder Singh Rekhi

    IPC分类号： A61K9/26 ,  A61K9/20 ,  A61K9/40 ,  A61K9/48 ,  A61K9/50 ,  A61K9/54 ,  A61K9/56 ,  A61K9/58 ,  A61K31/4458 ,  A61K47/32 ,  A61P11/00 ,  A61P25/00 ,  A61P43/00 ,  A61K9/14

    CPC分类号： A61K9/5084

    摘要： The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在操作中以脉冲或双峰方式递送活性成分。 多微粒改性释放组合物包含立即释放组分和改性释放组分; 所述立即释放组分包含含有颗粒的第一组活性成分，所述改性释放组分包含第二组活性成分，所述活性成分含有涂覆有控释涂层的颗粒; 其中操作中的速释组分和改进释放组分的组合以脉冲或双峰方式递送活性成分。 本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型。 通过多微粒改性释放组合物实现的血浆曲线有利于减少患者对活性成分的耐受性，并通过降低剂量频率提高患者依从性。

    Drug delivery kit and method of packaging the same
    5.
    发明授权
    Drug delivery kit and method of packaging the same 失效
    药物递送试剂盒和包装方法相同

    公开(公告)号：US6000548A

    公开(公告)日：1999-12-14

    申请号：US102841

    申请日：1998-06-23

    申请人： Izrail Tsals

    发明人： Izrail Tsals

    IPC分类号： B65B1/30 ,  A61B19/02 ,  A61J1/06 ,  A61J1/14 ,  A61M5/00 ,  A61M5/14 ,  A61M5/24 ,  B65D69/00

    CPC分类号： A61M5/002 ,  A61B50/33 ,  A61J1/062 ,  A61M5/14 ,  Y10S206/807

    摘要： An improved drug delivery kit and method of packaging the same. The method includes providing a tray having first and second recesses for receiving a drug delivery device and drug cartridge respectively, and an opening in the tray within the second recess, placing the drug delivery device in the first recess, covering the tray with a sealable material, sealing the material to the tray so as to create a seal around the first and second recesses, so as to isolate the first recess from the second recess, sterilising the tray, and inserting the drug cartridge through the opening and into second recess. The opening is sized such that insertion of the drug cartridge through the opening and into the second recess elastically stresses the tray and removal of the drug cartridge from the opening irreversibly deforms the tray, thereby creating a tamper-proof drug delivery kit.

    摘要翻译： 改进的药物递送试剂盒及其包装方法。 该方法包括提供具有分别用于接收药物输送装置和药物盒的第一和第二凹部的托盘和在第二凹部内的托盘中的开口，将药物输送装置放置在第一凹部中，用可密封材料覆盖托盘 将所述材料密封到所述托盘，以便在所述第一和第二凹部周围产生密封，以便将所述第一凹部与所述第二凹部隔离，对所述托盘进行灭菌，以及将所述药物盒插入所述开口并进入第二凹部。 开口的尺寸使得药物盒通过开口插入到第二凹部中弹性地迫使托盘并且药物盒从开口中的移除不可逆地使托盘变形，从而产生防窜改药物递送套件。

    Controlled absorption diltiazen formulation for once-daily administration
    7.
    发明授权
    Controlled absorption diltiazen formulation for once-daily administration 失效
    受控吸收性硫酸盐制剂每日一次给药

    公开(公告)号：US5616345A

    公开(公告)日：1997-04-01

    申请号：US334864

    申请日：1994-11-04

    申请人： Edward J. Geoghegan ,  Seamus Mulligan ,  Donald E. Panoz

    发明人： Edward J. Geoghegan ,  Seamus Mulligan ,  Donald E. Panoz

    IPC分类号： A61K9/50 ,  A61K31/55 ,  A61K31/554 ,  A61K9/16

    CPC分类号： A61K31/55 ,  A61K31/554 ,  A61K9/5078 ,  A61K9/5084

    摘要： A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of the diltiazem from the pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration.

    摘要翻译： 用于口服给药的地尔硫卓丸剂制剂包含与有机酸结合的地尔硫卓核心或其药学上可接受的盐，以及包围核心的多层膜，并含有主要比例的药学上可接受的成膜水不溶性合成 聚合物和较小比例的药学上可接受的成膜水溶性合成聚合物。 膜中的层数和水溶性与水不溶性聚合物的比例有效地允许从口服释放二氧化硫以粒子的速度允许其控制吸收二十四小时。

    Diltiazem formulation
    10.
    发明授权
    Diltiazem formulation 失效
    地尔硫卓制剂

    公开(公告)号：US4891230A

    公开(公告)日：1990-01-02

    申请号：US120952

    申请日：1987-11-16

    申请人： Edward J. Geoghegan ,  Seamus Mulligan ,  Donald E. Panoz

    发明人： Edward J. Geoghegan ,  Seamus Mulligan ,  Donald E. Panoz

    IPC分类号： C07D281/10 ,  A61K9/00 ,  A61K9/16 ,  A61K9/22 ,  A61K9/48 ,  A61K9/50 ,  A61K9/52 ,  A61K9/62 ,  A61K31/55 ,  A61K31/554 ,  A61P3/00 ,  A61P9/08 ,  A61P9/10

    CPC分类号： A61K9/5078 ,  A61K31/55 ,  A61K31/554 ,  Y10S514/965

    摘要： A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (Paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KCl at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 80% of the total diltiazem is released after six hours of measurement and not less than 85% of the total diltiazem is released after 13 hours of measurement.